Related Experiment Video
Updated: Aug 10, 2026
09:37
A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation
Published on: March 15, 2018
[OPG, anti-rANKL antibody]
1Center for Experimental Medicine, Institute of Medical Science, University of Tokyo, Nagahama Institute for Biochemical Science, Oriental Yeast Co., Ltd.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|September 17, 2005
Summary
The study identifies receptor activator of NF-kappaB ligand (RANKL) and osteoprotegerin (OPG) as key regulators of osteoclast function. Inhibiting RANKL with OPG or antibodies shows promise for treating bone diseases like osteoporosis.
Area of Science:
- Molecular Biology
- Bone Biology
- Immunology
Context:
- Osteoclast differentiation and function are critical processes in bone remodeling.
- Dysregulation of these processes contributes to pathological bone destruction.
- The RANKL-RANK signaling pathway is a central mechanism in osteoclast development.
Purpose:
- To elucidate the molecular mechanisms regulating osteoclast differentiation and function.
- To identify key signaling molecules involved in bone metabolism.
- To explore therapeutic targets for bone-related diseases.
Summary:
- Identification of key molecular players including receptor activator of NF-kappaB ligand (RANKL), RANK (receptor activator of NF-kappaB), and osteoprotegerin (OPG/osteoclastogenesis inhibitory factor).
- RANKL-RANK signaling is crucial for both physiological osteoclast development and pathological bone destruction.
- OPG and anti-RANKL antibodies function as specific RANKL inhibitors, demonstrating therapeutic potential.
Impact:
- Provides fundamental insights into the molecular basis of osteoclast biology.
- Highlights the therapeutic potential of targeting the RANKL-RANK pathway.
- Suggests applications for OPG and anti-RANKL antibodies in managing osteoporosis and rheumatoid arthritis.
Related Concept Videos
01:15Receptor Downregulation in MVBs
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
01:26Receptor Tyrosine Kinases
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...